$ELDN
Eledon Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023011011 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.997M $2.790M $12.70M
YoY Change -7.04% -12.89% -3.29%
% of Gross Profit
Research & Development $8.113M $7.250M $27.08M
YoY Change 22.28% 17.28% 14.09%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.11M $10.04M $88.43M
YoY Change 12.69% 6.98% 272.56%
Operating Profit -$11.11M -$88.43M
YoY Change 12.69% 139.86%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $338.0K $304.0K $462.0K
YoY Change -6860.0% 6500.0%
Pretax Income -$10.77M -$58.38M -$87.97M
YoY Change 9.21% 522.1% 138.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.77M -$58.38M -$87.97M
YoY Change 9.21% 563.0% 154.97%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$6.16
Diluted Earnings Per Share -$0.75 -$4.09 -$6.16
COMMON SHARES
Basic Shares Outstanding 13.78M 13.76M 14.29M
Diluted Shares Outstanding 14.29M 14.29M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.49M $56.41M $56.41M
YoY Change -39.38% -33.51% -33.51%
Cash & Equivalents $46.50M $56.40M $56.41M
Short-Term Investments
Other Short-Term Assets $47.00K $28.00K $3.109M
YoY Change 176.47% -17.65% -11.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.90M $59.52M $59.52M
YoY Change -38.35% -32.63% -32.63%
LONG-TERM ASSETS
Property, Plant & Equipment $647.0K $739.0K $739.0K
YoY Change -4.15% -3.78% -3.78%
Goodwill $0.00
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $369.0K $150.0K $150.0K
YoY Change 7.27% -62.5% -62.5%
Total Long-Term Assets $33.40M $33.28M $33.28M
YoY Change -59.29% -59.52% -59.52%
TOTAL ASSETS
Total Short-Term Assets $48.90M $59.52M $59.52M
Total Long-Term Assets $33.40M $33.28M $33.28M
Total Assets $82.31M $92.79M $92.79M
YoY Change -49.0% -45.59% -45.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.852M $2.200M $2.200M
YoY Change 177.97% 21.35% 21.35%
Accrued Expenses $2.626M $4.275M $4.275M
YoY Change 35.92% 65.19% 65.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.478M $6.475M $6.475M
YoY Change 85.19% 47.13% 47.13%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $284.0K $383.0K $383.0K
YoY Change -18.86% -4.25% -4.25%
Total Long-Term Liabilities $284.0K $383.0K $383.0K
YoY Change -18.86% -4.25% -4.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.478M $6.475M $6.475M
Total Long-Term Liabilities $284.0K $383.0K $383.0K
Total Liabilities $7.514M $8.610M $8.610M
YoY Change 48.5% 31.39% 31.39%
SHAREHOLDERS EQUITY
Retained Earnings -$213.6M -$202.9M
YoY Change 71.15% 76.59%
Common Stock $288.4M $287.0M
YoY Change 2.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.79M $84.18M $84.18M
YoY Change
Total Liabilities & Shareholders Equity $82.31M $92.79M $92.79M
YoY Change -49.0% -45.59% -45.59%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$10.77M -$58.38M -$87.97M
YoY Change 9.21% 563.0% 154.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$9.924M -$9.480M -$28.42M
YoY Change 21.68% 2.95% -1.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -9.924M -9.480M -28.42M
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000
Net Change In Cash -9.924M -9.480M -28.42M
YoY Change 21.68% 2.95% -3.19%
FREE CASH FLOW
Cash From Operating Activities -$9.924M -$9.480M -$28.42M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36620
CY2022 dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
19900 MacArthur Boulevard
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 550
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2022 dei City Area Code
CityAreaCode
(949)
CY2022 dei Local Phone Number
LocalPhoneNumber
238-8090
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
ELDN
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
33518551
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13776788
CY2022 dei Auditor Firm
AuditorFirmId
170
CY2022 dei Auditor Name
AuditorName
KMJ Corbin & Company LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56409000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84833000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3513000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
59518000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
88346000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
739000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
768000
CY2021Q4 us-gaap Goodwill
Goodwill
48648000
CY2022Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2021Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
400000
CY2022Q4 us-gaap Assets
Assets
92793000
CY2021Q4 us-gaap Assets
Assets
170548000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2200000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1813000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
363000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2219000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6475000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4401000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
383000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
400000
CY2022Q4 us-gaap Liabilities
Liabilities
8610000
CY2021Q4 us-gaap Liabilities
Liabilities
6553000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13776788
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13776788
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14306788
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14306788
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287034000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
278880000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202865000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114899000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92793000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170548000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27080000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23735000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12700000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13132000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2022 us-gaap Operating Expenses
OperatingExpenses
88428000
CY2021 us-gaap Operating Expenses
OperatingExpenses
36867000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-88428000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-36867000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
462000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87966000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36860000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.16
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.16
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.33
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.33
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285254
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285254
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14819582
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14819582
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7904000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
163995000
CY2022 eldn Cancellation Of Common Stock In Exchange For Preferred Stock Value
CancellationOfCommonStockInExchangeForPreferredStockValue
1000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8153000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2022 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
373000
CY2021 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
195000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8153000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7904000
CY2021 eldn Deferred Tax Liability
DeferredTaxLiability
2354000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-654000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2095000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2081000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2143000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-367000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-200000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28424000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28913000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
450000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-449000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28424000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29362000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84833000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84833000
CY2022 eldn Increase Decrease In Operating Lease Asset And Liability Due To Lease Modification
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
344000
CY2021 eldn Increase Decrease In Operating Lease Asset And Liability Due To Lease Modification
IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
825000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1000
CY2022 eldn Common Stock Exchanged For X One Non Voting Convertible Preferred Stock
CommonStockExchangedForXOneNonVotingConvertiblePreferredStock
1000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-88000000.0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-202900000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56400000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, including goodwill, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
CY2022 eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9300000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9300000
CY2022Q4 eldn Fair Value Assets Transfers Between Level Amount
FairValueAssetsTransfersBetweenLevelAmount
0
CY2021Q4 eldn Fair Value Assets Transfers Between Level Amount
FairValueAssetsTransfersBetweenLevelAmount
0
CY2022Q4 eldn Fair Value Liabilities Transfers Between Level Amount
FairValueLiabilitiesTransfersBetweenLevelAmount
0
CY2021Q4 eldn Fair Value Liabilities Transfers Between Level Amount
FairValueLiabilitiesTransfersBetweenLevelAmount
0
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48600000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-87966000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-34506000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.16
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.16
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.33
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.33
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285254
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285254
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14819582
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14819582
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8139155
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1087174
CY2022 eldn Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Taxes Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxesExpenseBenefit
0
CY2022 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement.
CY2022Q4 eldn Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
823000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1344000
CY2022Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2115000
CY2021Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
2039000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
143000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
96000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
28000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
34000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3109000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3513000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022 eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P2Y
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1909000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1411000
CY2021Q4 eldn Accrued Severance Current
AccruedSeveranceCurrent
104000
CY2022Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
1826000
CY2021Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
454000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
65000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
167000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
83000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3912000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2219000
CY2020Q4 us-gaap Goodwill
Goodwill
48648000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q4 us-gaap Goodwill
Goodwill
48648000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
48648000
CY2022Q4 us-gaap Goodwill
Goodwill
0
CY2022Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
403000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
283000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
387000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
208000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
344000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
825000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M28D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0300
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
378000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
388000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
766000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
746000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
363000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
383000
CY2022Q4 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2022Q4 eldn Contingent Liability
ContingentLiability
0
CY2021Q4 eldn Contingent Liability
ContingentLiability
0
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-88159000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37055000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
193000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
195000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87966000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36860000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2746000
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
392000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2354000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2022 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2021 eldn Effective Federal And State Income Tax Rate
EffectiveFederalAndStateIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-18473000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7741000
CY2022 eldn State Income Taxes Net Of Federal Tax Benefits
StateIncomeTaxesNetOfFederalTaxBenefits
-2678000
CY2021 eldn State Income Taxes Net Of Federal Tax Benefits
StateIncomeTaxesNetOfFederalTaxBenefits
-445000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1046000
CY2021 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
651000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
986000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
651000
CY2022 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
3000
CY2021 eldn Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
2000
CY2022 eldn Income Tax Reconciliation State Tax Rate Differential
IncomeTaxReconciliationStateTaxRateDifferential
274000
CY2021 eldn Income Tax Reconciliation State Tax Rate Differential
IncomeTaxReconciliationStateTaxRateDifferential
235000
CY2022 eldn Nol True Up
NOLTrueUp
-337000
CY2021 eldn Nol True Up
NOLTrueUp
-991000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
114000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
146000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
11697000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9460000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6440000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2354000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15230000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12531000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2294000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1356000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
452000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
296000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5264000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2874000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1867000
CY2022Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1595000
CY2021Q4 eldn Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1713000
CY2022Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
179000
CY2021Q4 eldn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
171000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27888000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17934000
CY2022Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
178000
CY2021Q4 eldn Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
171000
CY2022Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
7787000
CY2021Q4 eldn Deferred Tax Liabilities In Process Research And Development
DeferredTaxLiabilitiesInProcessResearchAndDevelopment
7192000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7965000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7363000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21675000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12323000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1752000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1469000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
764000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
914000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
712000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
281000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
7000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2664000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1469000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6400000
CY2022 eldn Period For Which Cumulative Change In Ownership Annual Use Net Operating Loss And Research And Development Credit Carryforwards
PeriodForWhichCumulativeChangeInOwnershipAnnualUseNetOperatingLossAndResearchAndDevelopmentCreditCarryforwards
P3Y
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 eldn Number Of Stock Compensation Plans
NumberOfStockCompensationPlans
3
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3621479
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.63
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
702836
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.69
CY2021 eldn Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
-174
CY2021 eldn Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice
4.73
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
110164
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.50
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213977
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.33
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1267700
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
263644
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.12
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5218033
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5218033
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.69
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3076338
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.72
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.81
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.84
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.05
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.10
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.018
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8153000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7904000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10500000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M

Files In Submission

Name View Source Status
R17.htm Edgar Link pending
0000950170-23-011011-index-headers.html Edgar Link pending
0000950170-23-011011-index.html Edgar Link pending
0000950170-23-011011.txt Edgar Link pending
0000950170-23-011011-xbrl.zip Edgar Link pending
eldn-20221231.htm Edgar Link pending
eldn-20221231.xsd Edgar Link pending
eldn-ex23_1.htm Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img115283225_0.jpg Edgar Link pending
img115283225_1.jpg Edgar Link pending
img115283225_2.jpg Edgar Link pending
img115283225_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
eldn-20221231_lab.xml Edgar Link unprocessable
eldn-20221231_cal.xml Edgar Link unprocessable
eldn-20221231_def.xml Edgar Link unprocessable
eldn-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eldn-20221231_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending